The prognosis of resistance to platinum drugs in patients with the serous ovarian cancer
The cytogenetic study of peripheral blood lymphocytes was carried out in patients with the serous ovarian cancer divided into three groups: platinum refractory patients (1st group), platinum-resistant patients (2nd group) andplatinum-sensitive (3rd group) patients. Aberrant cells met authentically more often (p<0,05) in 1st group (42,2±8,3%) thanin 2ndgroup (32,5±6,3%) and 3rd one (16,5±4,4%). Different fragile spectra of chromosomes sites were discovered in patients with the serous ovarian cancer in all groups. We've found 14 fragile sites, 12 of which coincide with classified ones: 10 fragile sites are common ones, but 2 sites belong to the rare fragile sites. Regions of fragile sites we found were of the same localization with chromosomal rearrangements found in tumors and in the ovarian cancer contain genes involved in cancer development. Chromosomal instability and the presence of certain fragile sites of chromosomes can be used as markers of platinum-sensitivity in patients with the serous ovarian cancer.